The anti-tumor immune response against neoantigens that are expressed by solid tumors is predominantly attributed to MHC-I-restricted CD8 cytotoxic T cells, but MHC-II-restricted CD4 T cells are also important drivers of anti-tumor immunity [61–63]. This evidence concerns the gene CD8A and neoplasm.